Vocxi Health, a breath diagnostics company focused on non-invasive, disease identification has partnered with S3 Connected Health, the specialist digital health partner for life science companies, to bring technology to market to change lung cancer detection and monitoring.
Vocxi Health has patented technology to deliver a smart device, the BreathEZ, designed to detect lung cancer from volatile organic compounds with just one minute of breathing. This technology aims to make late stage diagnoses a thing of the past, promising earlier detection and improved outcomes for patients. Lung cancer is responsible for over 1.8 million deaths globally every year, but early detection leads to a 10X improvement in survival rates.
Vocxi Health has partnered with S3 Connected Health for full end-to-end delivery of their digital health solution, and S3 Connected Health’s digital health platform Affinial, a platform for life science companies to create regulated digital health solutions, will be used as the basis upon which the custom mobile app and cloud-based solution will be built. Vocxi Health also plans to leverage Affinial’s efficiencies in scaling solutions to facilitate their future plans for the BreathEZ, including potential expansion into other disease areas.
Bill Betten, director of medtech solutions at S3 Connected Health, who has been working closely with Vocxi on this said: “This is an exciting journey upon which we’re embarking with Vocxi. It is a game-changing product that takes full advantage of our digital health system capabilities, including rapid deployment via our Affinial platform while providing a base for future growth to match Vocxi’s plans.”
Randy Schiestl, chief operating officer and board director at Vocxi Health, added: “We have proprietary technology, an experienced and motivated core team, trusted advisors, and global partners to meet commercialisation objectives. Vocxi partnering with S3 Connected Health has enabled the team to integrate mobile and cloud connectivity with confidence.”
